<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>130</id><JournalTitle>EVALUATING THE EXTRA OUTCOMES IN ADDING ZOLEDRONIC ACID YEARLY INFUSION TO CALCIUM VITAMIN D OVER CONVENTIONAL CALCIUM VITAMIN D SUPPLEMENTATION IN TREATING OSTEOPOROSIS</JournalTitle><Abstract>Evaluate the extra outcomes of adding Zoledronic acid yearly once infusion to Calcium and Vitamin D over the
conventional Calcium Vitamin D supplementation in treating osteoporosis. A baseline BMD test is done and the T score
was noted initially. Patients were randomized into two groups based on the use of yearly Zoledronic acid infusion along
with conventional Calcium and Vitamin D therapy. The patients were followed for the duration of one year to evaluate the
patient medication adherence and improvement in bone strength. The second BMD was taken after one year and the
change in T score was noted to evaluate the additional benefits of Zoledronic acid regimen over the patients with only
Calcium and Vitamin D.The interventions have transformed many patients from osteoporotic to ostiopenic, followed by
osteopenic to risk and risk to normal categories. The mean difference for change in T-sore among Hip and Spine was
observed as 0.6 and 0.5 respectively in those who treated with Zoledronic acid, only 0.4 and 0.4 was observed in those
who treated without Zoleronic acid. This difference in the change in T-score among the two groups is showing the
additional benefits of Zoledronic acid yearly once infusion along with Calcium and Vitamin D over the conventional
management only with Calcium and Vitamin D. The change in T score from the baseline score has shown the
effectiveness of drug therapy. Moreover drug therapy with Zoledronic acid yearly once infusion is showing greater impact
and additional benefits on improving the T score as well as bone strength of the patients compare to the patients received
only Calcium and Vitamin D..</Abstract><Email>robin.george793@gmail.com</Email><articletype>Research</articletype><volume>9</volume><issue>2</issue><year>2019</year><keyword>Additional,Benefits,Zoledronic acid,Conventional,Osteoporosis</keyword><AUTHORS>Dr. Sneha K Varghese,Dr. Robin George,Dr.Sindu.J.Punnoora</AUTHORS><afflication>Clinical Pharmacist, KIMS Hospital, Thiruvanandapuram - 695029, Kerala, India.,Assistant Professor, Department of Pharmacy Practice, Seven Hills College of Pharmacy, Tirupati, Andhra Pradesh, India.,General Physician, K.G. Hospital and Post Graduate Research Institute, Coimbatore, Tamil Nadu. India.</afflication></Article></Articles>